Business Wire

DC-SIREN

30.1.2024 13:08:28 CET | Business Wire | Press release

Share
AI-driven Siren 14 Introduces Officer Safety on Mobile and Simplifies Search

Siren, the company that provides an all-in-one investigation platform to Police and Sheriff's Departments, Intelligence and Law Enforcement Agencies, Fusion Centers and High Intensity Drug Trafficking Areas programs (HIDTAs) has launched a new AI-Powered search with mobile access as part of its latest release and its Siren for Law Enforcement product bundle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125060576/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New Simplified Search (Photo: Business Wire)

Siren provides a complete suite of investigation tools for contemporary challenges such as police vetting, “Smash and Grab” violence, VIP protection, trafficking, supply chain rime and maritime security.

Siren connects local classified information with external vendor data as well as data available from public sources (OSINT), to identify patterns, actors and events. Siren is now available on mobile devices to provide an additional layer of safety for front line officers.

The new AI-driven search dramatically reduces the complexity in connecting disparate intelligence. Complex links can be made by anyone from any department, using a basic language based search and without the need for analytical skills. According to Siren’s research, it takes at least six months for a new analyst to become productive. The simple interface naturally distributes the workload.

Siren makes it possible for front-line officers to background check suspects, companies and properties from a mobile device prior to criminal interactions and site raids. The new Siren innovation offers an extra layer of security, reducing the risk of unexpected dangers and providing fast actionable leads.

"Simple is hard and that’s what we have achieved with Siren 14.” said John Randles, CEO of Siren. “Siren can now provide complex connected intelligence to Command Staff and Uniformed Police without data science training. It’s a simple search just like using the internet or shopping online.” he concluded.

“The new ability to search in Siren will push the control of basic investigations and safety checks back out into the hands of those who need it most.” said Siren customer, Kathleen Miles, Head of Client Relations, and Co-Founder of Ex Arca, an open-source research firm. “Siren mobile means that intelligence teams can focus on the work they are trained to do.” she added.

"Siren is now accessible to the whole department which is a complete game changer. Democratising intelligence like this is a change not seen in twenty years of technology." commented Bob Griffin, Chairman of Siren.

About Siren

Siren is an all-in-one investigation platform used by law enforcement, intelligence agencies and corporations to safeguard people, assets and networks. Siren links data from open source, vendors and classified sources to surface unconnected intelligence. Siren’s patented technology is uniquely search-based providing a simple interface and advanced reporting for investigations at Enterprise speed and scale.

In November 2023, Siren achieved 9th in Deloitte’s Technology Fast 50. Siren received €12 million funding in 2023 and was named a Gartner Cool Vendor in 2020. For more information, visit www.siren.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240125060576/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release

Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye